INTRODUCTION AND OBJECTIVES: Urinary tract infection
(UTI) is a serious complication of neurogenic bladder (NB), is associated with resistant organisms and causes autonomic dysreflexia & reduced quality of life. UTI diagnosis in NB is difficult due to sensory changes prohibiting reports of traditional LUTS. Near Infrared spectroscopy (NIRS) has previously reported diagnostic capabilities in pediatric UTI. Objective: examine telemedicine with home monitoring of bladder parameters including NIRS for early UTI diagnosis & symptom reduction.
METHODS: Prospective cohort study (NLUTD with recurrent UTI). Subjects served as their own controls x 6 months run in then completed adaptive telemedicine. CONCLUSIONS: Subjects on telemedicine with home monitoring experienced a significant reduction in UI & high compliance with visits even in high tetraplegia. Home monitoring of blood pressure and acquisition of bladder NIRS was feasible. Telemedicine can improve NB management and increase healthcare access. Bladder NIRS in the SCI population is feasible and could provide an adjunctive method for early UTI detection in this population with high AMR.
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MP07-07 DECLINE IN RATES OF BLADDER AUGMENTATION AND INCONTINENT DIVERSION AFTER INTRODUCTION OF ONABOTULINUM TOXIN A IN PATIENTS WITH NEUROGENIC BLADDER
Rita Jen*, Irene Crescenze, Anne Cameron, Paholo Barboglio-Romo, Priyanka Gupta, Bahaa Malaeb, John Stoffel, Quentin Clemens, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: In 2011 the FDA approved onabotulinum toxin A (BTX-A) in patients with NGB. This allowed for patients refractory to medical therapy an alternative to proceeding directly to augmentation cystoplasty or urinary diversion. We sought to identify the impact BTX-A had on augmentation and diversion rates over the last 11 years. We hypothesize that the less morbid BTX-A led to a decline in rates of bladder augmentation and diversion for patients with NGB.
METHODS: The number of bladder augmentations, diversions, and BTX-A injections performed per year for the last 11 years at a single institution were identified retrospectively and adjusted based on number of NGB patient visits. Patients with prior pelvic radiation, cancer in the pelvis, revision bladder surgery, and isolated continence channels were excluded.
RESULTS: There were 3303 patients with NGB diagnoses evaluated at 9867 distinct encounters at a single center over 11 years and 156 patients who underwent either bladder augmentation or incontinent diversion for NGB. The cohort was 58.3% (91/156) female. Median age was 45 years (18-80). Seventy patients underwent bladder augmentation ranging 4-10 per year and 86 underwent diversions ranging 4-12 per year (Figure 1) . After adjusting for the total number of NGB patients seen by urology each year, the odds of having augmentation in 2015 -2017 vs. 2007 -2009 and odds of having an incontinent diversion was 0.55 p[0.048) (Figure 2 ). The proportion of visits for BTX-A injections in the total NGB cohort increased from 10.46% (55/526) in 2012 to 21.92% (217/990) in 2017 (OR[2.40, 95%CI 1.75-3.30, p<0.001) . Increased number of patients failed BTX-A prior to surgery in 2015 -2017 vs. 2007 -2009 .
CONCLUSIONS: The rates of augmentation and incontinent diversion are declining while rates of BTX-A therapy are increasing over the past decade. More data are needed to determine if BTX-A represents a permanent or only a temporary solution for management of NGB.
